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overlapping pathologic processes in the aging brain
contribute to dementia, including Alzheimer’s disease de-
mentia [1]. This pathophysiological complexity creates
significant controversies in clinicopathologic correlations
of the underlying causes of dementia and has implica-
tions in identifying potential targets for disease modifica-
tion. The recent perspective article by Rabinovici et al.
[2] summarizes important presentations made at Research
Roundtable meeting October in 2014 within the overall
theme of understanding the role of additional/comorbid
pathologies in the aging brain and their potential interac-
tion with clinical Alzheimer’s disease and other dementia
phenotypes. On the basis of a systematic review of the
relevant literature the article postulates that indeed de-
mentia syndromes are much more commonly related to
multiple neuropathologies especially in older individuals,
rather than a single underlying process [2]. Going one
step further, the roundtable participants explore how
mixed pathologies should influence the design of clinical
trials and drug development in dementia. In summary, the
authors suggest that a better understanding of thethor. Tel.: 617 643 3876; Fax: 617 726 5346.
iswanathan1@partners.org
16/j.trci.2016.11.001
he Authors. Published by Elsevier Inc. on behalf of the Alzhe
commons.org/licenses/by-nc-nd/4.0/).complexity of clinical and neuropathologic phenotypes
is urgently needed. This knowledge could be then trans-
lated and integrated into biochemical and neuroimaging
candidate biomarkers that will better detect multiple
pathologies and enable better-targeted therapeutic devel-
opments in the field [2].
The topic is indeed highly complex. The complexity stems
not only for comorbid neurodegenerative pathologies in
the setting for Alzheimer’s disease (rigorously discussed in
the article), but also from concomitant cerebrovascular pa-
thologies. This latter aspect might deserve another roundta-
ble meeting to be defined and deserves some more thorough
discussion in the context of dementia trials. Cerebrovascular
disease is highly prevalent in the elderly brain [3]. However,
the impact of these lesions on dementia, the prevalence of
vascular dementia, and the pathophysiological pathways
and implications behind characteristic in vivo imaging find-
ings and ex vivo pathologic lesions are still under debate.
Three types of pathologies affecting cerebral blood vessels
can contribute to dementia: (1) atherosclerosis, (2) cerebral
amyloid angiopathy, and (3) nonamyloid-related small
vessel disease pathology, including lipohyalinosis and arte-
riolosclerosis [3,4]. These cerebrovascular pathologies can
all lead to various downstream cerebrovascular lesions and
associated focal and diffuse brain tissue injury, including
large and small vessel infarcts, microinfarcts, microbleeds,imer’s Association. This is an open access article under the CC BY-NC-ND
A. Charidimou and A. Viswanathan / Alzheimer’s & Dementia: Translational Research & Clinical Interventions 2 (2016) 281-282282and white matter lesions. Of particular interest is the role of
cerebral amyloid angiopathy, a well-defined entity, almost
invariably present in Alzheimer’s disease brains, that seems
to affect the pathologic and clinical phenotype of dementia,
including lowering the threshold for clinically overt demen-
tia [5–7]. In a recent community-based autopsy study, cere-
bral amyloid angiopathy was found to be an important
determinant of Alzheimer’s disease dementia and decline
in multiple cognitive domains in old age [1]. This effect
was independent and over and above Alzheimer’s disease
pathology and other common age-related neuropathologies
[1]. Similar findings were recently reported for cerebral
atherosclerosis and arteriolosclerosis in the setting of Alz-
heimer’s disease dementia [8].
Taken together, these and other observations support a key
role for cerebral vessel pathologies in Alzheimer’s disease
dementia, but they might be under-recognized risk factors.
An unmet need in fully elucidating the contribution of cere-
brovascular pathologies is the lack of standardized criteria
for their neuropathologic assessment (including related le-
sions) in human postmortem brains [3]. This lack of stan-
dardization is reflected in this roundtable perspective
article [2], which nicely summarizes the pathologic staging
of neurodegenerative pathologies, but a similar scheme for
cerebrovascular pathologies (and the complexities to define
these) was not identified and suggested.
The conclusions from this Research Roundtable meeting [2]
will help to better inform clinical practice and future
research trial design. In should be emphasized however, in
the design of these future trials the role of vascular brain
injury must be carefully considered [9]. Because cerebrovas-
cular disease burden might be modifiable, the implications
of aggressive treatment of vascular risk factors, especially
hypertension (with clear definitions of blood pressure tar-
gets), in disease-modifying Alzheimer’s disease trials may
be important for the treatment effect. A pragmatic trial (as
defined by the authors) might attempt to target both clinical
Alzheimer’s disease progression and future stroke [10], as
these two outcomes interact to lower the threshold for de-
mentia and neurologic dysfunction in elderly individuals.
Thus, the extent to which vascular care and blood
pressure-lowering interventions can reduce dementia in
elderly patients is testable in future trials in the field [11].
Finally, clear criteria to identify robust biomarkers of cere-bral small vessel disease are also an urgent priority and are
the focus of a new multicenter National Institute of Health
funded initiative (http://www.ninds.nih.gov/funding/
funding_announcements/rfa/RFA-NS-16-020.htm). Redefin-
ing our approach to dementia by considering the role of mul-
tiple cerebral pathologies in the disease, rather than only
focusing on a single underlying pathology is of critical
importance. This approach will improve our understanding
of the pathophysiology of dementia and eventually help us
design effective therapies for this devastating disease.References
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